ALS treatment
adapted for
the real world

It is now standard practice in the UK to prescribe riluzole to all ALS patients at diagnosis1

But tablets are not easy for ALS patients to take. To continue with treatment, many patients and carers resort to crushing tablets, but the risks of doing so outweigh the benefits:2,3

Emotional Practical Clinical Legal
Worry of misdosing4 Difficult to administer4 No stability data3 Unlicensed use and greater accountability7
Guilt of causing aspiration (carer)4 Unpleasant metallic taste4 Under-dosing due to lipophilic properties and low solubility in water5,6
Fear of choking (patient)4 Temporary numbness in the mouth3
Fear of not being able to take medication4 Potential tube blockage and choking4

It is illegal to crush riluzole tablets to aid consumption now that an alternative formulation is available7,8

  • Professional judgement should be used to make a decision in the best interests of each patient, to optimise treatment and to minimise risk of harm9

Any decision to recommend off-license use must be fully documented and confirm that the patient/carer has no concerns regarding safety10

  • Failure to do so contravenes the Medicines Act10
In clinical trials, riluzole extended life by up to 2.8 months
In real-world studies, riluzole extended life by up to 21 months
to Teglutik®

Teglutik® is the first oral liquid suspension formulation of riluzole, the only licensed treatment for patients with amyotrophic lateral sclerosis (ALS), the most common type of motor neuron disease (MND).

This site provides information on Teglutik® and ALS for UK-based healthcare professionals and patients. Please select from the buttons below to tailor the content to your needs:

I am a UK healthcare professional
I am not a healthcare professional

For additional information about MND you can visit the Motor Neurone Disease Association website. The Motor Neurone Disease Association is the only national charity in England, Wales and Northern Ireland focused on MND care, research and campaigning